

4TH ANNUAL MUSIC CITY FALL CLASSIC

Nashville 2022



TABLE OF CONTENTS

Table of Contents	1
Welcome	2
Industry Partners	3
Schedule	4
Course Notes	6
Speakers	8
Upcoming Conferences	10
Information, Awareness, & Improvement Talks	13
Diamond Industry Partners	15
Gold Industry Partners	19
Silver Industry Partners	28
Supporter Industry Partners	33

WELCOME



If this is your first conference thank-you for joining us and for the many who have previously joined us in-person or streaming, we thank-you for your continued support. The philosophy of The Optometric Education Consultants (OEC) is to help optometrists enhance care of their patients through timely, clinically pertinent, and highly interactive education. OEC assembles top clinical educators to deliver high-quality COPE-approved continuing education in a relaxed, comfortable setting.

We could not offer the pricing, meals and guest speakers without our exhibitors and ask you to take some time to visit with them during breaks. We implement a BINGO game to encourage vendor-attendee interaction. Instead of gift cards our three winners can receive a (a) full refund of registration, (b) 50% refund of registration or (c) 25% refund of registration.

For those Florida doctors wanting TQ we will send a link for the exams to all attendees 1-2 days after the conference. The cost of the exams is \$10 per course and certificates are issued immediately upon taking the online test. CE Broker will be updated a few days later. If you do not need the exams of course simply delete the link.

Schedules are developed with your comfort in mind, so you have time to learn, interact with exhibitors and, very importantly, relax and enjoy yourself. Regardless of the location, our conferences are always COPE-accredited and Florida-approved. If you hold a license outside of Florida and need additional hours consider our webinar and/or live conference schedule. We have added enduring courses that can be taken at your leisure also. Our enduring and webinar courses are all COPE-approved but we ask that you confirm that this type of education is acceptable for your state.

To view upcoming webinars bookmark: [webinars](#)

To view enduring courses bookmark: [enduring](#)

To view upcoming in-person conferences details: [Live Conferences](#)

We are still in the planning stage for some of our 2023 conferences but below is what we can share this weekend.

Pittsburgh Power Hours, February 18-19

Marriott Pittsburgh Airport

CE Sarasota, March 5-6

The Westin Sarasota

Mid-Winter Getaway, April 14-16

Arizona Grand Resort and Spa

Sunshine State Summer Conference, June 16-18

Orlando World Center Marriott

Mackinac Island OEC Summer Meeting August 18-20

Mission Point Hotel

Music City Fall Classic TBD

Nashville, TN

Again thank-you for trusting OEC with your education needs and enjoy Nashville!

Greg, Joe, and Vanessa

INDUSTRY PARTNERS



Diamond Industry Partners

BAUSCH + LOMB

 **NOVARTIS**

 **TearCare**
System

Platinum Industry Partners

UPNEEQ
(oxymetazoline hydrochloride
ophthalmic solution), 0.1%

 **heru**

Gold Industry Partners

GLAUKOS
Transforming Glaucoma Therapy

 **biotissue**

Contamac

 **NOTAL VISION**
The Ophthalmic Home
Diagnostic Services Provider

 **OPTIKAM**

 **weave**

Silver Industry Partners

 **CooperVision**

 **neuroLens**
Relief is in Sight

 **PHARMANEX**
Trevor Crabtree, OD
618-889-3825
trevkarcab7@aol.com

 **SCIENCEBASED**
HEALTH

Supporter Industry Partners

Bruder
Better. By Design.

SCHEDULE



Friday October 21, 2022			
Time	Course Title	CE Hrs	CEE/TQ
7:00 am – 7:30 am	Registration & Breakfast with Exhibitors	None	None
7:30 am – 8:00 am	Welcome and Information, Awareness, and Improvement Industry Talk Breakfast Heru	None	None
8:00 am – 9:40 am	Therapeutic Innovations: The Game Changers Jessica Steen, OD	2	Yes
9:40 – 10:10 am	Introductions and Break with Exhibitors	None	None
10:10 am – 11:50 am	Clinical Discussions in Glaucoma Jessica Steen, OD and Joseph Sowka, OD	2	Yes
11:50 am – 1:10 pm	Exhibitor Lunch Talks B&L 12:30 – 1:00	None	None
1:10 pm – 2:50 pm	Rheumatology, Thyroid Dysfunction, and the Eye Greg Caldwell, OD	2	Yes
2:50 pm- 3:20 pm	Break with Exhibitors	None	None
3:20 pm – 4:10 pm	Mistakes to Avoid in Glaucoma Management Joseph Sowka, OD	1	No
4:15 pm – 5:15 pm	Complimentary Workshop Hosted by Optikam		
Saturday October 22, 2022			
Time	Course Title	CE Hrs	CEE/TQ
7:00 am – 7:30 am	Registration & Breakfast with Exhibitors	None	None
7:30 am – 8:00 am	Welcome and Information, Awareness, and Improvement Industry Talk Breakfast RVL - Cecelia Koetting, OD	None	None
8:00 am – 9:40 am	Advanced Dry Eye Treatment and Management Cecelia Koetting, OD	2	Yes
9:40-10:00 am	Break with Sponsors		
10:00 am – 10:50 am	Eyes Are Going Viral: When is a Red Eye Not Just A Red Eye? Cecelia Koetting, OD	1	No
10:55 am -11:45 am	A New Era in Cataract and Refractive Surgical Management Cecelia Koetting, OD	1	No

SCHEDULE



11:45 am – 1:00 pm	Break with Sponsors & Lunch Talks Novartis 12:00 – 12:30 Jay Mattheis, MD, MSPH, FACS Sight Sciences 12:30 – 1:00 Cecelia Koetting, OD	None	None
1:00 pm – 2:40 pm	Neural Pearls Joseph Sowka, OD	2	Yes
2:40 pm – 3:00 pm	Break and Exhibit Hall Closes	None	None
3:00 pm – 3:50 pm	OCT and OCT Angiography Something Old and Something New – Retina Clinical Pearls Greg Caldwell, OD	1	No

3:50

Conference Adjourns

Sunday October 23, 2022			
Time	Course Title	CE Hrs	CEE/TQ
7:00 am – 7:30 am	Registration & Breakfast with Exhibitors	None	None
7:30 am – 8:00 am	Welcome and Information, Awareness, and Improvement Industry Talk Breakfast	None	None
8:00 am – 9:40 am	Evolving Trends in Retinal Vascular Disease Jessica Steen, OD	2	Yes
9:40 am – 9:50 am	Break (split room)		
9:50 am-11:30 am <i>Concurrent</i>	Pharmaceutical Update 2022 Greg Caldwell, OD	2 hrs. CEE	Yes
9:50 am-11:30 am <i>Concurrent</i>	Prevention of Medical Errors Joseph Sowka OD	2 hrs.	No
11:30 am- 1:10 pm <i>Concurrent</i>	Opioid Prescribing Issues for Patient and Practitioner Greg Caldwell, OD	2 hrs. CEE	Yes
11:30 am- 1:10 pm <i>Concurrent</i>	Florida Jurisprudence Joseph Sowka, OD	2 hrs.	No

COURSE NOTES



COURSE NOTES

DOWNLOAD

Therapeutic Innovations: The Game Changers

Jessica Steen, OD

DOWNLOAD

Clinical Discussions in Glaucoma

Jessica Steen, OD and Joseph Sowka, OD

DOWNLOAD

Rheumatology, Thyroid Dysfunction, and the Eye

Greg Caldwell, OD

DOWNLOAD

Mistakes to Avoid in Glaucoma Management

Joseph Sowka, OD

DOWNLOAD

Advanced Dry Eye Treatment and Management

Cecelia Koetting, OD

DOWNLOAD

Eyes Are Going Viral: When is a Red Eye Not Just A Red Eye?

Cecelia Koetting, OD

DOWNLOAD

A New Era in Cataract and Refractive Surgical Management

Cecelia Koetting, OD

DOWNLOAD

Neural Pearls

Joseph Sowka, OD

DOWNLOAD

OCT and OCT Angiography Something Old and Something New – Retina Clinical Pearls

Greg Caldwell, OD

DOWNLOAD

Evolving Trends in Retinal Vascular Disease

Jessica Steen, OD

DOWNLOAD

Pharmaceutical Update 2022

Greg Caldwell, OD

DOWNLOAD

Prevention of Medical Errors

Joseph Sowka OD

DOWNLOAD

Opioid Prescribing Issues for Patient and Practitioner

Greg Caldwell, OD

DOWNLOAD

Florida Jurisprudence

Joseph Sowka, OD

SPEAKERS



Greg Caldwell, OD, FAAO

Greg Caldwell, OD, is a 1995 graduate of the Pennsylvania College of Optometry. He completed a one-year residency in primary care and ocular disease at The Eye Institute in Philadelphia Pennsylvania. He is a fellow of the American Academy of Optometry (AAO) and a Diplomate of the American Board of Optometry (ABO).

He currently works in Duncansville and Johnstown, Pennsylvania as an ocular disease consultant. Dr. Caldwell's primary focus is the diagnosis and management of anterior and posterior segment ocular disease and he has been a participant in multiple FDA investigations. Dr. Caldwell has lectured extensively throughout the county and over twelve countries internationally. In 2010 he served as President of the Pennsylvania Optometric Association (POA) and served on the AOA Board of Trustees 2013-2016. He is President of the Blair/Clearfield Association for the Blind.



Joseph Sowka, OD, FAAO, Diplomate

Dr. Joseph Sowka is an attending optometric physician at Center for Sight in Sarasota, Florida, a large medical-surgical practice where he focuses on glaucoma management and neuro-ophthalmic disease. He was formerly Professor of Optometry at Nova Southeastern University College of Optometry for 28 years where he served as Chief of The Advanced Care Service and Director of the Glaucoma Service at the College's Eye Institute. He was the Program Coordinator and Supervisor for the Ocular Disease Residency. Dr. Sowka is a founding member of both the Optometric Glaucoma Society and Optometric Retina Society. He is also the Founder and Chair of the Neuro-Ophthalmic Disorders in Optometry Special Interest Group for the American Academy of Optometry. Dr. Sowka is a Glaucoma Diplomate of the American Academy of Optometry. He is a partner and co-owner of Optometric Education Consultants.

SPEAKERS



Jessica Steen, OD, FAAO


Dr. Steen is an Assistant Professor at Nova Southeastern University College of Optometry, where she serves as an attending optometric physician and instructs ocular pharmacology. She is a Fellow of the American Academy of Optometry, a Diplomate of the American Board of Optometry, a member of the Optometric Glaucoma Society, and serves as Secretary on the Palm Beach County Optometric Association.



Cecelia Koetting, OD

Dr. Koetting practices at the MD/OD practice Hines Sight in Denver, CO. Her primary focus is in anterior segment and ocular surface disease, neuro-optometry, and peri-operative care. Dr. Koetting is fellow in the American Academy of Optometry, a diplomate of the American Board of Optometry, active member of AOA and has served as both local and state officers in AOA. She was named young Optometrist of the year in 2019 by the state of Virginia, receiving the Vanguard of the Year Award. Dr. Koetting lectures locally, nationally and internationally at conferences and has written for multiple publications.

UPCOMING CONFERENCES



Pittsburgh Power Hours
February 18-19, 2023



CE Sarasota, FL
March 5-6, 2023



Mid-Winter Get-Away
Phoenix
April 14-16, 2023

UPCOMING CONFERENCES



**Florida Summer
Conference, Orlando
June 16-18, 2023**



**Mackinac Island
Summer Meeting
August 18-20, 2023**



**5th Annual Music City
Fall Classic Nashville
Date TBA**

INFORMATION, AWARENESS, & IMPROVEMENT TALKS

This activity is supported with
unrestricted educational grants
from Alcon, Horizon,
and Sun Pharmaceuticals.



Dark Adaptation can be **illuminating.**



Shine a spotlight on age-related macular degeneration
with Heru's market-leading AMD portfolio.

9

Vision Exams

5

CPT Codes

1

Wearable Platform

Stop by our booth at OEC Nashville to learn more



UPLIFTED

Give Ptosis Patients an EYE-OPENING Lift
With a Daily Drop of Upneeq® (oxymetazoline
hydrochloride ophthalmic solution), 0.1%¹

The only FDA-approved prescription eyedrop proven to lift
upper eyelids in adults with acquired blepharoptosis (low-lying lids)¹

Learn more at Upneeq.com.

INDICATION

Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- Alpha-adrenergic agonists as a class may impact blood pressure. Advise Upneeq patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
- Use Upneeq with caution in patients with cerebral or coronary insufficiency or Sjögren's syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
- Upneeq may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
- Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.

ADVERSE REACTIONS

Adverse reactions that occurred in 1-5% of subjects treated with Upneeq were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation, and headache.

DRUG INTERACTIONS

- Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
- Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see next page for Brief Summary of full Prescribing Information.

Reference: 1. Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%. [Prescribing Information].

RVL
PHARMACEUTICALS, INC.

Distributed by: RVL Pharmaceuticals, Inc.
Bridgewater, NJ 08807
Customer Service 1-866-600-4799
Upneeq is a registered trademark of RVL Pharmaceuticals, Inc.
©2021 RVL Pharmaceuticals, Inc.
PM-US-UPN-0197 01/21

Learn more at Upneeq.com



UPNEEQ.
(oxymetazoline hydrochloride
ophthalmic solution), 0.1%*

*Each mL of Upneeq contains 1 mg of oxymetazoline hydrochloride, equivalent to 0.09 mg (0.09%) of oxymetazoline free base.

Eye-Opening Possibilities

DIAMOND INDUSTRY PARTNERS

This activity is supported with
unrestricted educational grants
from Alcon, Horizon,
and Sun Pharmaceuticals.





THE HORSEPOWER YOU NEED TO LOWER IOP

Powerful IOP reduction with excellent tolerability^{1,2}

VYZULTA delivered **up to 9.1 mmHg mean IOP reduction** from baseline in pivotal trials.^{1,2*}

TAKE A TEST RIDE AT VYZULTAHCP.COM

*Pivotal study designs: Two Phase 3, randomized, multicenter, parallel-group studies, APOLLO and LUNAR, evaluating noninferiority of once-daily VYZULTA vs twice-daily timolol maleate 0.5% in patients with open-angle glaucoma or ocular hypertension. Primary endpoint was IOP measured at 9 assessment time points in study eye. APOLLO (VYZULTA, n=284; timolol, n=133) and LUNAR (VYZULTA, n=278; timolol, n=136).^{2,3}

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

- Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
- Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
- Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
- Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
- There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
- Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
- Most common ocular adverse reactions with incidence $\geq 2\%$ are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

For more information, please see Brief Summary of full Prescribing Information on adjacent page.

References: 1. VYZULTA Prescribing Information. Bausch & Lomb Incorporated. 2. Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. *Ophthalmology*. 2016;123(5):965-973. 3. Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. *Am J Ophthalmol*. 2016;168:250-259.



Intelligent Heat in Your Expert Hands.

Unobstructed care in your future.



**Treat DED by targeting
obstructive MGD with
the TearCare® System.**

Indications for Use: The TearCare® System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.

The TearCare® System may not be right for everyone. Please see Instructions for Use or visit [TearCare.com](https://www.tearcare.com) for contraindications, warnings, precautions and adverse events.



Exciting news—Significantly broader coverage for your Medicare patients: **Xiidra is now covered for nearly 3 out of 4* Medicare Part D patients!**



XIIDRA IS NOW
on the lowest branded co-pay tier and
requires no prior authorization on:

- SilverScript Medicare
- Aetna® Medicare
- Cigna® Medicare
- Express Scripts® Medicare
- EGWP WellCare™ Classic PDP

EFFECTIVE JULY 1, 2022



Choose Xiidra as your first-choice
prescription dry eye disease treatment.
Prescribe with confidence for a 90-day Rx.



*Approximately 70% as of 7/1/22. Coverage information from data on file.

DRF Fingertip Formulary®

Novartis Pharmaceuticals Corp; July 2022.

Novartis does not endorse any particular plan.

Inclusion on formulary or formulary status does not imply superior clinical efficacy or safety. Data from data on file are accurate as of 7/1/2022 and are subject to change without notice.

XIIDRA, the XIIDRA logo and ii are registered trademarks of Novartis AG. All trademarks are the property of their respective owners.

GOLD INDUSTRY PARTNERS

This activity is supported with
unrestricted educational grants
from Alcon, Horizon,
and Sun Pharmaceuticals.



NOW FROM GLAUKOS

Using Photrex® Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrex® (riboflavin 5'-phosphate ophthalmic solution), and the KXL® system, the iLink™ corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*1



GET THERE IN TIME

iLink™ is the only FDA-approved cross-linking procedure that slows or halts progressive keratoconus to help you preserve vision.

Now from GLAUKOS
LEARN MORE AT GLAUKOS.COM

INDICATIONS

Photrex® Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) and Photrex® (riboflavin 5'-phosphate ophthalmic solution) are indicated for use with the KXL system in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Corneal collagen cross-linking should not be performed on pregnant women.

IMPORTANT SAFETY INFORMATION

Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects.

The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all of the side effects of the corneal collagen cross-linking treatment. For more information, go to www.livingwithkeratoconus.com to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

*Photrex® Viscous and Photrex® are manufactured for Avedro. The KXL system is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

REFERENCE: 1. Photrex [package insert]. Waltham, MA: Glaukos, Inc; 2016.

MA-01953A

Glaukos® is a registered trademark of Glaukos Corporation. iLink™ is a trademark of Glaukos Corporation. Photrex®, Photrex® Viscous, and the KXL® system are registered trademarks of Avedro, a Glaukos company. All rights reserved.

©2022



GLAUKOS

Regenerate.
Restore.
Recover.



Prokera[®]

A Vision of Modern Healing

Prokera biologic corneal bandages
help empower the eye's healing
abilities to expedite a return to normal.

HyClear^o

The ONLY Balanced Analytic Hypochlorous Acid™

for Essential Daily Eyelid Health Management



What is HyClear?

HyClear is the only balanced analytic hypochlorous acid for essential daily eyelid health management. With a broad-spectrum of antimicrobial activity from the pure hypochlorous acid .01%, HyClear kills most ocular pathogens in 15 seconds*.

Sell HyClear in your practice!

To create a wholesale account visit gethyclear.com and click on the physicians page to get started!

*Reduction in microbial growth in solution has not shown to correlate with a reduction of infection in patients. No clinical studies have been performed to evaluate reduction of infection.

Nutrifill^o

Scleral, Hybrid, and GP Lens Insertion Solution

Nutrifill preservative free insertion solution is a sterile isotonic buffered solution containing electrolytes (calcium, magnesium, potassium, phosphate, and sodium). Nutrifill is indicated as an insertion solution for large diameter (scleral), hybrid and gas permeable (GP) contact lenses.

What Makes Nutrifill Great?

- 5 electrolytes
- pH 7.4
- 0smolality 300
- 10ml Single-Use Ampoules

Patients Can Order Online at Nutrifill.com

Purchase a single carton or bundle and save with a 3-pack.

1 Month

(35 single-use ampoules)

\$31.50

3 Month

(3 Cartons)

\$79.50

(Save \$15)

Sell Nutrifill in your practice!

To create a wholesale account visit nutrifill.com and click on the physicians page to get started!

gethyclear.com hello@gethyclear.com

nutrifill.com

hello@nutrifill.com

Contamac^o

AMD Standard of Care is Not Enough



IRIS REGISTRY

20/83 VA

Average at wet AMD diagnosis according to IRIS Registry real-world data¹



HOME STUDY

≥20/40 VA

Average at wet AMD diagnosis with ForeseeHome²



Early Detection Helps Preserve Vision

ForeseeHome is a **remote monitoring** program for at-risk dry AMD patients that helps **detect wet AMD earlier** and alerts you of changes.



ForeseeHOME™
AMD Monitoring Program

Remote patient monitoring leads to better outcomes and stronger optometric practices

✓ FDA Cleared ✓ Medicare Covered

- Differentiate your practice
- No cost to your practice
- Solidify long-term relationships with your patients
- Strengthen your referral relationships with qualified wet AMD referrals

The Key to Successful Home Monitoring

NOTAL VISION MONITORING CENTER



Engagement & Education
Benefits Verification & Authorization
Continuous Monitoring



Practice Workflow Implementation
Remote Patient Management
Vision Alert Management



GET STARTED TODAY

1-855-600-3112

Mon-Fri, 8 AM to 6 PM EST

www.foreseehome.com/doctor



ForeseeHome is a registered trademark, and the ForeseeHome AMD Monitoring Program and logo and the Notal Vision logo are trademarks of Notal Vision. © 2020 Notal Vision, Inc. All rights reserved.

References: 1. Rao P et al. *Ophthalmology*, 2018;125(4):522-528. 2. Domalpally A, Clemons TE, Bressler SB, et al. *Ophthalmol Retina*, 2019;3(4):326-335.

See website for FDA Indication for Use.

SM-068.03

Digital Health Solution Supports Early Disease Detection



A dedicated remote monitoring program with an AI-enabled digital health solution supports the detection of wet AMD conversion between office visits, when it's difficult to manage the acute onset of wet disease that requires timely treatment.

NOTAL VISION MONITORING CENTER

The key to success - partnering with a remote monitoring provider

A remote ophthalmic monitoring center and Medicare credentialed provider, led by practicing ophthalmologists and supported by certified ophthalmic professionals, we offer a comprehensive nationwide age-related macular degeneration (AMD) home monitoring service to referring practices and their patients.



The Monitoring Center, provider of the ForeseeHome® AMD Monitoring Program, supports practices at no cost and manages all the heavy lifting, including patient benefits verification, onboarding, device training, and continuous engagement—all done remotely at the patient's convenience.



GET STARTED TODAY

1-855-600-3112

Mon-Fri, 8 AM to 6 PM EST

www.foreseehome.com/doctor

Prevent AMD Vision Loss with Digital Healthcare

Partner with a digital healthcare provider like the **Notal Vision Monitoring Center** to close the loop between doctors and patients between office visits with the ForeseeHome AMD Monitoring Program.

✓ FDA Cleared

✓ Medicare Covered

✓ No Cost to Practice



PHYSICIAN
REFERRAL TO
MONITORING
CENTER



BENEFIT
VERIFICATION



DEVICE TRAINING



PATIENT
ENGAGEMENT



COMPLIANCE
MONITORING



DEVICE PROVISIONING



ALERT NOTIFICATION



PATIENT
ENCOUNTER
WITH
PHYSICIAN

ForeseeHOME™
AMD Monitoring Program

ForeseeHome is a remote monitoring service for at-risk dry AMD patients that alerts the provider of changes to help detect wet AMD earlier. We take care of everything once a referral is sent.



**GET
STARTED**



www.foreseehome.com/doctor

1-855-600-3112

Mon-Fri, 8 AM to 6 PM EST



THE NEW OPTIKAM POSTURE DEVICE

A unique device that uses an electronic tilt sensor to capture and monitor the customer pantoscopic tilt in real time.

Remote Capture


Capture customer posture with a push of a button, all from within the OptikamPad app.

Live Posture Reading

A posture indicator displays the current live customer pantoscopic tilt reading in relation to the captured one. Monitor customer posture in real-time for a faster and more precise validation. Capturing the correct customer posture has never been easier.

Demonstrate the Benefits of Multiple Pairs

Display the benefits of owning multiple pairs by showing the fitting crosses drawn on the lens for up to three different captured posture types



Is social distancing a new norm?

Social distancing is likely to be the norm for the foreseeable future. Customers will likely perceive traditional tools such as the hand-held pupillometer, the sharpie or the distometer as overly intrusive.

OptikamPad takes all of your position-of-wear measurements with 1 single image and minimal human-to-human contact.



www.optikam.com



The all-in-one communication platform for optometry practices.

A collage of various Weave interface elements. At the top center is a large smartphone screen displaying a text conversation with "Smith Partners". The messages include: "This is Dr. Smith's office. Sorry we missed your call. How can we help you?", "Hi, I know it's Sunday and you're closed but my tooth is really hurting. I don't know what's wrong. Can you see me first thing Monday?", and "I'm sorry to hear that. Dr. Smith can see you at 10am tomorrow. Does that work for you?". To the left of the phone is a smaller screen showing an appointment confirmation: "Thank you! Your appointment request has been submitted." with a sailboat icon and a note that the office staff will review the request. Below the phone is a patient profile card for "American Fork" featuring "Amelia Adams" with her phone number (801) 555-5555 and location, along with "View" and "Ignore" buttons. To the right of the phone are three notification cards: a 5-star review from "Julia Gavin" for "Smith Partners", a "Payment request of \$75.00" from "Smith Partners", and a "Payment received" notification for "Amount: \$75.00". At the bottom right is a patient profile card for "Franklyn Digs" with his last visit date (October 3), next visit date (July 3), birthday (Tomorrow), and overdue balance (\$235.00).

SILVER INDUSTRY PARTNERS

This activity is supported with
unrestricted educational grants
from Alcon, Horizon,
and Sun Pharmaceuticals.



When it comes to myopia control in children who are
8-12 years of age at the initiation of treatment,

MiSight[®] 1 day

is the ONE for myopia control*

Year 7 results from the international
MiSight[®] 1 day clinical study found
that the mean axial elongation
showed **no evidence of rebound**^{1,2†}



MiSight[®] 1 day
for daily wear



How can myopia control with
MiSight[®] 1 day benefit your practice?
Learn more at **CooperVision.com**

Disclaimer: The stability of the myopia reduction effect 1-year post-treatment is being further evaluated in a post-approval study in the U.S. as a condition of FDA approval for MiSight[®] 1 day.

***Indications for use:** MiSight[®] 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

[†]Preliminary international study data shows that, on average, for children that discontinued treatment at age 14-19 following 3 or 6 years of MiSight[®] 1 day wear, the eye growth reverted to age-expected average myopic progression rates.

References: 1. Chamberlain P, Arumugam B, et al. Myopia progression on cessation of dual-focus contact lens wear: MiSight[®] 1 day 7-year findings. *Optom Vis Sci.* 2021;98:E-abstract 210049. 2. Hammond D, Arumugam B, et al. Myopia control treatment gains are retained after termination of dual-focus contact lens wear with no evidence of a rebound effect. *Optom Vis Sci.* 2021;98:E-abstract 215130.



Prism is ~~Niche~~

~~Unnecessary~~

~~Not Worth It~~

~~Problematic~~

~~Complicated~~

~~Difficult~~

~~Tricky~~

~~A Specialty~~

~~Avoidable~~

~~Challenging~~

~~Poison~~

The Future

Become a provider at neuro lenses.com





Visit us at our booth to get your carotenoid/diet/lifestyle assessment
Join us Friday or Saturday, October 21 or 22, 2022, for Cocktails, Snack, and [Free Workshop](#)
Immediately following the last lectures - On property location to be announced at the meeting
Learn about the technology, science, revenue, and pharmaceutical grade nutraceuticals
Learn about the importance of full antioxidant supplementation

FREE WORKSHOP

Measure Carotenoids, But Supplement the Whole Retina and Eye

Going Beyond Lutein and Zeaxanthin – the Eye and Body deserve more!

Register For Workshop

**A NEW STANDARD FOR CAROTENOID AND MACULAR PIGMENT MEASUREMENT
NUTRITION IS THE KEY TO KEEPING THE EYES AND THE BODY HEALTHY**

PATIENTS WANT GUIDANCE AND DIRECTION
PATIENTS ARE NOW EXPECTING PREVENTATIVE MEDICINE

LEARN HOW TO ADD REVENUE TO YOUR PRACTICE

**TAKE ADVANTAGE OF THE SHOW SPECIAL
\$2950 (\$650 off) and additional 900 scans while supplies last**

NOW, YOU CAN ADD OCULAR AND SYSTEMIC NUTRITION TO YOUR PRACTICE IN A MORE EFFECTIVE
WAY WITH CONFIDENCE AND HIGH PATIENT SATISFACTION

- INNOVATIVE TECHNOLOGY - NONINVASIVE OBJECTIVE MEASUREMENT (30 SECONDS)
- DIRECT CORRELATION TO MACULAR PIGMENT
- KNOW YOUR STARTING POINT - MEASURE IN 30 SECONDS
- KNOW IF YOUR TREATMENT IS WORKING- CLINICALLY PROVEN AND GUARANTEED
- NO INVENTORY
- SIMPLE AND EASY TO IMPLEMENT- FULLY OPERATIONAL THE FIRST WEEK
- COMPREHENSIVE TRAINING AND COACHING – TURNKEY SYSTEM



"The Biophotonic Scanner is Optometry's Bridge to Wellness." – Stuart Richer, OD, PhD
Ocular Wellness and Nutrition Society – Past President

Take advantage of the OEC Show Special and save \$650 at the meeting

Implementation Specialist
20 years of clinical carotenoid measurement
Trevor Crabtree, OD
Trevkarcrab7@aol.com
618-889-3825 cell #



— MEET THE — EXPERT

OEC's Music City Fall Classic 2022
SBH Booth, Saturday, October 22nd, 9:40-10:00 AM

**LEARN HOW A LEADING DRY EYE EXPERT
INCORPORATES HYDROEYE IN HER OWN PRACTICE**

Cecilia Koetting, OD, FAAO will discuss the science behind HydroEye, offer dry eye clinical pearls, answer questions, and review how a clinically validated supplement can help grow your dry eye practice.

Visit the SBH booth Saturday from 9:40-10:00 AM



Cecilia Koetting, OD, FAAO

Dr. Koetting practices at the MD/OD practice Hines Sight in Denver, CO. Her focus is in anterior segment and ocular surface disease, neuro-optometry, and peri-operative care. Dr. Koetting is fellow in the American Academy of Optometry, a diplomate of the American Board of Optometry, and an active member of AOA. Dr. Koetting lectures locally, nationally and internationally at conferences and has written for multiple publications.



HYDROEYE®

**Powerful Dry Eye Support
With GLA: The Dry Eye Omega**

Stop by the booth and receive
a **FREE 60-DAY SUPPLY.**

SUPPORTER INDUSTRY PARTNERS

This activity is supported with
unrestricted educational grants
from Alcon, Horizon,
and Sun Pharmaceuticals.



Providing Effective Dry Eye Care Helps Grow Your Practice

Looking for ways to grow your practice? Effectively treating the dry eye patient can help.

What Makes the Bruder Mask #1 Doctor Recommended?

Bruder compresses are scientifically designed from the inside out. A key differentiator between the Bruder Moist Heat Eye Compress and other masks is the chemistry of the beads inside. Only the Bruder compress contains patented MediBeads®. This is an important distinction.

MediBeads® are silver-infused. Incorporating silver into the bead structure ensures pure, clean, moist heat with every use, helping to repel bacteria and keep eyelids clean.

Eye care practitioners have found that moist heat compresses containing silver-infused MediBeads can help promote healthy outcomes. The Bruder compress helps clear oil glands and allows natural oils to flow back onto the eye to relieve discomfort. It is a patient favorite for its unique design and comfortable fit.



Want to know more about the Bruder family of products?

Visit bruder.com/pro or email eyes@bruder.com



BRUDER LID HYGIENE PRODUCTS



NEW COUNTER DISPLAY and RETAIL PACKAGE



Purchase at order.bruder.com or call 888-827-8337 to speak to a representative.

Bruder | Better. By Design.
©2022 Bruder Healthcare Company Alpharetta, GA 30004